These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28304146)

  • 1. Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes.
    Garg M; Ghanim H; Kuhadiya ND; Green K; Hejna J; Abuaysheh S; Torre B; Batra M; Makdissi A; Chaudhuri A; Dandona P
    Diabetes Obes Metab; 2017 Sep; 19(9):1306-1311. PubMed ID: 28304146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes.
    Dubé MC; D'Amours M; Weisnagel SJ
    Diabetes Obes Metab; 2018 Jan; 20(1):178-184. PubMed ID: 28722271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study.
    Patel NS; Van Name MA; Cengiz E; Carria LR; Weinzimer SA; Tamborlane WV; Sherr JL
    Diabetes Technol Ther; 2017 Nov; 19(11):618-622. PubMed ID: 29068709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus.
    Lucidi P; Porcellati F; Cioli P; Candeloro P; Marinelli Andreoli A; Bolli GB; Fanelli CG
    Diabetes Technol Ther; 2020 Jan; 22(1):57-61. PubMed ID: 31411498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed-Loop System in Type 1 Diabetes: A Randomized Open-Labeled Crossover Design Trial.
    Ilkowitz JT; Katikaneni R; Cantwell M; Ramchandani N; Heptulla RA
    J Diabetes Sci Technol; 2016 Sep; 10(5):1108-14. PubMed ID: 27184690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes.
    Kuhadiya ND; Ghanim H; Mehta A; Garg M; Khan S; Hejna J; Torre B; Makdissi A; Chaudhuri A; Batra M; Dandona P
    J Clin Endocrinol Metab; 2016 Sep; 101(9):3506-15. PubMed ID: 27490915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventive effects of octreotide (SMS 201-995) on diabetic ketogenesis during insulin withdrawal.
    Diem P; Robertson RP
    Br J Clin Pharmacol; 1991 Nov; 32(5):563-7. PubMed ID: 1954071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Turnover and splanchnic metabolism of free fatty acids and ketones in insulin-dependent diabetics at rest and in response to exercise.
    Wahren J; Sato Y; Ostman J; Hagenfeldt L; Felig P
    J Clin Invest; 1984 May; 73(5):1367-76. PubMed ID: 6715541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus.
    Mader JK; Jensen L; Ingwersen SH; Christiansen E; Heller S; Pieber TR
    Clin Pharmacokinet; 2016 Nov; 55(11):1457-1463. PubMed ID: 27282158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of liraglutide on dietary lipid-induced insulin resistance in humans.
    Koska J; Lopez L; D'Souza K; Osredkar T; Deer J; Kurtz J; Salbe AD; Harman SM; Reaven PD
    Diabetes Obes Metab; 2018 Jan; 20(1):69-76. PubMed ID: 28605158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial.
    Kramer CK; Zinman B; Choi H; Connelly PW; Retnakaran R
    J Clin Endocrinol Metab; 2015 Oct; 100(10):3702-9. PubMed ID: 26230296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of free fatty acids, insulin, glucagon and adrenaline on ketone body production in humans.
    Miles JM; Haymond MW; Gerich JE
    Ciba Found Symp; 1982; 87():192-213. PubMed ID: 7042239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical characterization of ketosis-resistant young diabetics of northern India. In vivo effects of i.v. glucose, s.c. epinephrine and i.v. glucagon and in vitro effects of anti-insulin serum on adipose tissue lipolysis.
    Krishna Ram B; Sachdev G; Chopra A; Karmarkar MG
    Acta Diabetol Lat; 1984; 21(2):141-51. PubMed ID: 6433609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liraglutide for treating type 1 diabetes.
    Dejgaard TF; Frandsen CS; Holst JJ; Madsbad S
    Expert Opin Biol Ther; 2016; 16(4):579-90. PubMed ID: 26926662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach.
    Crisci I; Aragona M; Politi KS; Daniele G; Del Prato S
    Acta Diabetol; 2015 Dec; 52(6):1129-33. PubMed ID: 26293127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
    Østoft SH
    Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of intramyocellular lipids during hypoglycemia in patients with intensively treated type 1 diabetes.
    Bernroider E; Brehm A; Krssak M; Anderwald C; Trajanoski Z; Cline G; Shulman GI; Roden M
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5559-65. PubMed ID: 15998784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study.
    Kumarathurai P; Anholm C; Fabricius-Bjerre A; Nielsen OW; Kristiansen O; Madsbad S; Haugaard SB; Sajadieh A
    J Hypertens; 2017 May; 35(5):1070-1078. PubMed ID: 28129251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon.
    Gerich JE; Lorenzi M; Bier DM; Schneider V; Tsalikian E; Karam JH; Forsham PH
    N Engl J Med; 1975 May; 292(19):985-9. PubMed ID: 804137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty acid-independent inhibition of hepatic ketone body production by insulin in humans.
    Keller U; Gerber PP; Stauffacher W
    Am J Physiol; 1988 Jun; 254(6 Pt 1):E694-9. PubMed ID: 3287950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.